Document is current
Any future updates will be listed below
-
Authors
Schulz, Christian
Vilchez-Vargas, Ramiro
Öcal, Elif
Koch, Nadine
Puhr-Westerheide, Daniel
Burnell, Lu Fornés
Hirner-Eppeneder, Heidrun
Benckert, Julia
Pech, Maciej
Reimer, Peter
Verslype, Chris
Kuhl, Christiane
Tran, Albert
Ricke, Jens
Malfertheiner, Peter
Alunni-Fabbroni, Marianna https://orcid.org/0000-0002-9710-1662
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 30 June 2025
First Online: 10 July 2025
Declarations
:
: The SORAMIC trial (EudraCT 2009-012576-27, NCT01126645) was approved by the institutional review boards of all 38 participating centers and was conducted according to the ethical principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all participants.
: Not applicable.
: CS has received honoraria for lectures from Juvisé Pharmaceutics, Astellas and the Falk Foundation. CS has served in the Data Safety Monitoring Board or Advisory Board from Sanofi, Astella and Juvisé Pharmaceutics. CV has received consulting fees from IPSEN, AstraZeneca and Bayer and has received honoraria for lectures from IPSEN and Astra Zeneca.
